At the request of 23 public- and private-sector sponsors—including major life sciences companies as well as U.S. and international regulators such as the FDA and NIH—the Institute of Medicine (IOM) created a multidisciplinary committee to address that critical question. In a new report, the committee provides guiding principles, strategies and recommendations for responsibly sharing clinical trial data. Manatt partner Deven McGraw, a member of the IOM committee, shares firsthand insight into the report’s findings and implications at a new webinar, “Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk.”

During the webinar, presented through PharmaVoice, you’ll learn how business models, academic culture and sponsor and investigator incentives need to change to support the sustainable sharing of clinical trial data. Don’t miss this important opportunity to:

• Discover the committee’s four key recommendations for sharing clinical trial data responsibly.
• Explore the guiding principles for sharing clinical trial data, and the committee’s approach to applying them.
• Examine the roles and responsibilities of key stakeholders, including participants, funders and sponsors, regulatory agencies, investigators, research institutes and universities, journals, disease advocacy organizations and professional societies.
• Understand what data should be shared—and when.
• Identify approaches for mitigating risks and creating a true learning system for sharing clinical trial data.
• Look ahead to the future of data sharing in a changing landscape, including addressing infrastructure, technical, work force and sustainability challenges.

Sharing clinical trial data can accelerate new discoveries, stimulate new research and drive the development of safer, more effective therapies. Find out how we can work together to create a culture of sharing while protecting the rights and interests of all stakeholders. This is a critical program for anyone involved in advancing medical treatments.